Table 3.
Live Attenuated Vaccine candidates (Source: WHO as per 15th October 2021) | |||||
---|---|---|---|---|---|
Candidate | Dose | Schedule | Route of Administration | Phase | Developer |
COVI-VAC | 1–2 |
Day 0 or Day 0 + 28 |
Intranasal |
Phase 1 |
Codagenix/Serum Institute of India |
MV-014–212, expresses the spike (S) protein | 1 | Day 0 | Intranasal |
Phase 1 |
Meissa Vaccines, Inc |